

Program	Tumor Type	Phase 1	Phase 2	Phase 3
ADCETRIS® brentuximab vedotin	Diffuse large B-cell lymphoma			*
	Hodgkin lymphoma (HL)			
	HL or PTCL (unfit for combination chemotherapy)		*	
	HL and PTCL		*	
	HL (pediatrics)			
	PTCL (<10% CD30 expression)		*	
	Metastatic solid tumors			
PADCEV® enfortumab vedotin-ejfv	Cisplatin eligible muscle invasive bladder cancer			*
	Cisplatin ineligible muscle invasive bladder cancer			*
	Untreated locally advanced or metastatic urothelial cancer			*
	Locally advanced or metastatic malignant solid tumors			
	Urothelial Cancer		*, **	
	Non-muscle invasive bladder cancer			
TUKYSA® tucatinib	HER2+ metastatic breast cancer, multiple trials			*
	High-risk adjuvant HER2+ breast cancer			*
	HER2+ metastatic gastroesophageal cancer		*	
	HER2+ metastatic breast cancer			
	Metastatic solid tumors HER2 alterations			
	HER2+ metastatic colorectal cancer		*	
	HER2+ metastatic gastrointestinal cancer			
TIVDAK® tisotumab vedotin-tftv	Recurrent or metastatic cervical cancer			*
	Recurrent or metastatic cervical cancer			
	Advanced solid tumors			
	Platinum-resistant ovarian cancer			
Ladiratumab vedotin	Metastatic triple-negative breast cancer			
	Locally advanced or metastatic solid tumors			
	Metastatic breast cancer			
Disitamab vedotin	HER2 expressing urothelial cancer		*	
SEA-CD40	Melanoma and NSCLC			
	Solid tumors			
SEA-TGT	Advanced solid tumors and lymphomas			
SEA-BCMA	Relapsed/refractory multiple myeloma			
SEA-CD70	Myelodysplastic syndrome and acute myeloid leukemia			
SGN-CD228A	Solid tumors			
SGN-B6A	Solid tumors			
SGN-STNV	Solid tumors			
SGN-B7H4V	Solid tumors			
SGN-PDL1V	Solid tumors			
SGN-ALPV	Solid tumors			

* Registrational intent ** Phase 1b/2 The safety and efficacy of the above investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration (FDA) or other regulatory authorities.